Highlights
- IperionX confirmed its ongoing commercial-scale titanium production in Virginia is advancing through customer qualification phases.
- The company’s patented titanium technologies have received multiple U.S. government awards and nearly USD 160 million in funding, including SBIR Phase III, ARPA-E, and Defense Production Act Title III programs.
- IperionX’s Virginia Titanium Manufacturing Campus has increased its projected capacity from 125 tpa to 200 tpa, with plans to reach approximately 1,400 tpa by mid-2027.
- The Titan Critical Minerals Project is on track to become shovel-ready by mid-2026.
IperionX Limited (NASDAQ:IPX) (ASX:IPX) shares fell 8.2% to AUD 5.15 on 17 November 2025, as the company responded to a short seller report released by Spruce Point Capital Management. The announcement detailed IperionX’s ongoing titanium production scale-up, validation of its patented technologies, and support from multiple U.S. Government programs.
IperionX Addresses Short Seller Report
IperionX confirmed that Spruce Point Capital did not engage with the company before releasing its report. The company emphasized its compliance with continuous disclosure requirements under ASIC, ASX, and SEC rules. IperionX highlighted its rigorous confidentiality, data-security, and intellectual-property controls, meeting U.S. Department of War contracting standards.
The company reiterated its focus on commercial-scale titanium production in Virginia, with operations advancing through customer qualification phases. IperionX stated that it will continue updating the market in line with regulatory obligations.
Validation of Patented Titanium Technologies
IperionX’s technologies have received multiple awards and funding from U.S. Government programs, including ARPA-E, Defense Production Act Title III, IBAS, and SBIR Phase III contracts. These programs involve competitive selection, technical due diligence, and ongoing performance assessments by U.S. Department of War experts.
Notable recognitions include winning the U.S. Air Force Research Laboratory’s Grand Challenge in 2023, receiving a 2023 R&D 100 award, and securing nearly USD 160 million in combined government funding. This support spans industrial-scale titanium production, titanium powder innovation, and development of the Titan Critical Minerals Project in Tennessee.
Operational Focus and Market Expansion
IperionX’s Virginia Titanium Manufacturing Campus has increased its projected capacity from 125 tpa to 200 tpa, with plans to reach ~1,400 tpa by mid-2027 under IBAS funding. The company continues to deliver titanium components for defense and commercial customers, including Ford automotive programs, Panerai watches, and U.S. Army platforms.
IperionX’s strategy leverages patented HAMR and HSPT processes to produce high-performance titanium components at lower costs, using upgraded titanium scrap and mineral feedstocks. The Titan Critical Minerals Project is progressing toward ‘shovel-ready’ status by mid-2026.
Financial Position and Management
As of 30 September 2025, IperionX held USD 79.2 million in cash and equivalents, with access to additional funding through government programs.
Disclaimer:
This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.
Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.
Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.
The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.
The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.
Kalkine does not issue, sell or deal in any financial products.
This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.
To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.
Copyright 2026 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Article, or its content, may be reproduced in any form without our prior consent.